Victoza CV label update confirmed
CV label update confirmedFriday evening, the FDA approved a cardiovascular benefit indication for Victoza; this follows the positive advisory committee vote on June 20 when the panel voted 17-2 in favour of Victoza reducing heart risk in type 2 diabetics. We thus see the approval in line with expectations, and expect only a moderate share price reaction following the FDA’s decision. We reiterate our HOLD recommendation and DKK310 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.